论文部分内容阅读
目的探讨非霍奇金淋巴瘤(NHL)患者在自体干细胞移植(ASCT)前后18F-脱氧葡萄糖(FDG)正电子发射计算机断层扫描(PET)显像评价预测患者无进展生存期(PFS)的价值。方法 43例NHL患者在ASCT前后均行18F-FDG PET/CT检查,ASCT后随访时间均>18个月。根据随访结果,将ASCT前18F-FDG PET显像阳性患者分为进展与无进展组,比较两者最大标准化摄取值(SUVmax)的平均值。采用Kaplan-Meier方法进行PFS分析,并对影响PFS与预后的一系列因素进行Cox回归分析。结果 ASCT前,20例18F-FDG PET显像阳性患者中13例出现疾病进展,其SUVmax平均值明显高于其余7例无进展者[(5.9±2.0)对(3.6±1.5),P=0.016]。ASCT前后18F-FDG PET显像为阴性和显像为阳性的患者PFS差别均有统计学意义(P<0.01)。Cox回归分析发现ASCT前后18F-FDG PET显像评价是预测PFS的最重要因素(P<0.05),且独立于其他变量。结论 ASCT前后18F-FDG PET显像评价对预测NHL预后可能有一定价值,值得更进一步研究。
Objective To investigate the value of 18F-FDG positron emission tomography (PET) imaging in the prediction of progression-free survival (PFS) in patients with non-Hodgkin’s lymphoma (NHL) before and after autologous stem cell transplantation (ASCT) . Methods 43 cases of NHL patients underwent 18F-FDG PET / CT before and after ASCT, and the follow-up time was> 18 months after ASCT. According to the follow-up results, the positive patients with pre-ASCT 18F-FDG PET imaging were divided into the progression-free group and the non-progression group. The mean normalized maximum SUVmax was compared. Kaplan-Meier method was used for PFS analysis, and Cox regression analysis was performed on a series of factors affecting PFS and prognosis. Results Thirteen of 20 patients with positive 18F-FDG PET imaging showed disease progression before ASCT, and the mean SUVmax was significantly higher than those of the remaining 7 patients without progression [(5.9 ± 2.0) vs (3.6 ± 1.5), P = 0.016 ]. There were significant differences in PFS between patients with positive and negative 18F-FDG PET imaging before and after ASCT (P <0.01). Cox regression analysis showed that the evaluation of 18F-FDG PET imaging before and after ASCT was the most important factor to predict PFS (P <0.05), and independent of other variables. Conclusion The evaluation of 18F-FDG PET imaging before and after ASCT may have some value in predicting the prognosis of NHL, which deserves further study.